“Oncimmune £25.6m minimum sales contracts across 12 countries” says CEO, Geoffrey Hamilton-Fairley

Geoffrey Hamilton-Fairley, CEO of Oncimmune said of the Interims: “Oncimmune continues to make excellent progress in delivering on the potential of our platform to detect up to four years earlier than other methods based on a simple, robust, blood test – a liquid biopsy.

We have recently entered an exclusive distribution and product development agreement in China which includes a GBP10m equity investment and GBP15.7m in minimum royalties. We have now secured agreements for 12 countries with minimum sales commitments of GBP25.6m. We have also entered a preliminary distribution partnership with a major US pulmonology salesforce which is progressing well and, if successful, should lead to a significant distribution agreement focused on the risk detection of indeterminate pulmonary nodules – a large and growing market.

With our R&D programme delivering new tests and commercial opportunities in personalised medicine and companion diagnostics, we are excellently placed to deliver value in the medium and long term.”

 

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) liquid biopsy platform technology, today announced its interim results for the half year ended 30 November 2017.

Corporate & Operational highlights (including post-period end)

EarlyCDT(R)-Lung Commercial Progress

   --     Framework agreement with Genostics Company Limited ("Genostics") for China signed

o Exclusive licence for the distribution, manufacturing and future development of all products related to the EarlyCDT(R) platform

o Royalty payments of 8% to 12.5% with minimum royalties over the first six years post market entry of GBP15.7 million, and GBP5 million (index linked) per year thereafter

o GBP10m equity investment in Oncimmune with first investment tranche of GBP7m completed on 29 January 2018

   --     New agreements signed in multiple territories

o EarlyCDT(R)-Lung kit has minimum payment guarantees of GBP7.9m over the next five years in Asia Pacific (not including China).

o EarlyCDT(R)-Lung kit has minimum sales commitment of approximately GBP2.0m over the next five years in Europe

— First commercial batches of the EarlyCDT(R)-Lung kit shipped to distributors for introductory testing prior to full market release

   --     Distributor base in the US being trained for the sale of our EarlyCDT(R)-Lung test

— Preliminary distribution partnership progressing well with a major US pulmonary sales force for the use of EarlyCDT(R)-Lung in assessing indeterminate lung nodules:

o Initial phase is expected to complete by the end of the month

o Following completion, the parties will assess the results and, if successful, it is expected that this should lead to a distribution agreement for the U.S. pulmonologists

   --     "Finger stick" test launched, increasing speed and simplicity of EarlyCDT(R)-Lung test

R&D and Trials

— Development of the kit version of our EarlyCDT(R) tests is helping expand our geographical reach and we expect to make significant progress on this going forward

   --     Validated EarlyCDT(R)-Liver test and on track to begin commercial sales in H1 2018

— NHS lung cancer screening trial is fully recruited: 12,210 patients with final study results in 2019

Personalised Medicine & Companion Diagnostics

— Presented data on the use of Oncimmune’s technology to predict disease recurrence in patients undergoing immunotherapy for malignant melanoma in collaboration with Scancell Holding plc

— Autoantibody “fingerprint” technology development progressing well; first publications presented at the IASLC in November 2017

o Reaffirmed the early detection capabilities of the EarlyCDT(R) platform with patients on average showing an early detection lead-time of four years

Board Changes

— Appointment of Dr. Annalisa Jenkins to the Company’s Board as an Independent Non-Executive Director

Financial Highlights

   --     Revenues of GBP0.1m (2016: GBP0.1m) generated from early sales of the EarlyCDT(R)-Lung test

— Loss before one-off and non-cash items of GBP3.04m (2016: GBP2.3m) reflecting recruitment of staff, product development and commercialisation activities

   --     GBP5.0m raised from new and existing investors 
   --     Cash balance at the period end was GBP6.3m (H1 2016: GBP7.6m)

— Post period end receipt of first tranche equity subscription of GBP7.0m from Genostics making the cash balance GBP11.8m at the time of these results

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oncimmune Holdings PLC

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The